ÂÜÀòÂÒÂ×

Thomas Engels is currently the VP of Clinical Affairs at LimFlow SA. Thomas has over ten years of experience in clinical affairs, strategic planning, and execution of global clinical trials. Prior to joining LimFlow, Thomas was the VP of Clinical Affairs at CardioKinetix Inc., where they were responsible for the company's clinical affairs globally. Thomas led the regulatory efforts that resulted in CE Mark and FDA approval for the company's products. Thomas also designed and implemented the US pivotal trial (PARACHUTE IV) and the Chinese approval study (PARACHUTE China).

Before CardioKinetix, Thomas was a Clinical and Regulatory Business Consultant at InGeneron Incorporation. Thomas has also served as the VP of Clinical Affairs at Claret Medical and Micell Technologies, where they were responsible for the execution of 1400pt European randomized post-marketing trial (DESSOLVE III) and a randomized Chinese approval trial (DESSOLVE C).

Thomas has a proven track record in leading global clinical trials and achieving regulatory approvals. Thomas is an expert in designing and implementing clinical strategies that result in successful outcomes for their company.

Thomas Engels has an MBA from Columbia Business School and another MBA from the University of California, Berkeley, Haas School of Business. Thomas also has a Project Management Certification from Stanford University in Advanced Project Management / Organizational Mastery. Their undergraduate degree is in Zoology from Louisiana State University.

Their manager is Dan Rose, CEO. They work with Paul Limmer - VP, Finance & Administration, Zachary Woodson - VP, Regulatory Affairs & Quality, and Theo Mastrokostopoulos - VP, Sales & Market Development.